EU High Court Upholds $63 Million Fine Against AstraZeneca
Fine levied for lying on patent applications to member states in an effort to keep the generic version of an ulcer med off the market
Europe's highest court upheld a $63 million fine against pharmaceutical giant AstraZeneca for blocking the generic version of its Losec ulcer medication in the EU marketplace.
The European Commission originally fined AstraZeneca $72 million in 2005, after finding that the company had deliberately lied to member state patent offices in an effort to extend its protection of Losec.
Hide Comments (0)
Editor's Note: As of February 29, 2024, commenting privileges on reason.com posts are limited to Reason Plus subscribers. Past commenters are grandfathered in for a temporary period. Subscribe here to preserve your ability to comment. Your Reason Plus subscription also gives you an ad-free version of reason.com, along with full access to the digital edition and archives of Reason magazine. We request that comments be civil and on-topic. We do not moderate or assume any responsibility for comments, which are owned by the readers who post them. Comments do not represent the views of reason.com or Reason Foundation. We reserve the right to delete any comment and ban commenters for any reason at any time. Comments may only be edited within 5 minutes of posting. Report abuses.
Please
to post commentsMute this user?
Ban this user?
Un-ban this user?
Nuke this user?
Un-nuke this user?
Flag this comment?
Un-flag this comment?